Revenue Breakdown
Composition ()
No data
Revenue Streams
bioAffinity Technologies Inc (BIAF) generates its revenue primarily from Laboratory services, which accounts for 100.0% of total sales, equivalent to $1.45M. Understanding this concentration is critical for investors evaluating how BIAF navigates market cycles within the Medical Equipment, Supplies & Distribution industry.
Profitability & Margins
Evaluating the bottom line, bioAffinity Technologies Inc maintains a gross margin of 27.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -158.56%, while the net margin is -349.30%. These profitability ratios, combined with a Return on Equity (ROE) of -245.18%, provide a clear picture of how effectively BIAF converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, BIAF competes directly with industry leaders such as CELZ and NDRA. With a market capitalization of $5.13M, it holds a significant position in the sector. When comparing efficiency, BIAF's gross margin of 27.00% stands against CELZ's -3019.27% and NDRA's N/A. Such benchmarking helps identify whether bioAffinity Technologies Inc is trading at a premium or discount relative to its financial performance.
